Mortality and Length of Stay Associated With Community-Acquired Escherichia coli and Staphylococcus aureus Bloodstream Infections: An Observational Study in 9 Low- and Middle-Income Countries
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciag275 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Jill Hopkins und 46 weiteren Autor:innen. Beteiligte Einrichtung: Cambodia Oxford Medical Research Unit, Angkor Hospital for Children, Siem Reap, Cambodia. Hauptthemen laut MEDLINE: Community-Acquired Infections, Staphylococcal Infections, Escherichia coli Infections, Bacteremia. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, World Health Organization.
Abstract (Originalsprache)
Background
Antimicrobial resistance disproportionally affects low- and middle-income countries. We calculated the burden of resistant and susceptible Escherichia coli and Staphylococcus aureus bloodstream infections (BSIs) in ACORN2, a prospective clinical surveillance study in adults and children.
Methods
Patients with culture-confirmed community-acquired susceptible and resistant E. coli (third-generation cephalosporin susceptible [3GC-S] and resistant [3GC-R]) and S. aureus (methicillin-resistant [MRSA] and methicillin-susceptible [MSSA]) BSIs were compared against blood culture–negative patients (controls). Cause-specific hazard ratios (HRs) were calculated for competing events of in-hospital mortality and discharge alive. Length of hospital stay (LOS) was calculated.
Results
From 22 802 blood cultures taken, there were 329 E. coli (177 [53.8%] 3GC-R) and 363 S. aureus (132 [36.4%] MRSA) BSIs. In-hospital mortality was 8.4% for controls, 20.1% for E. coli (20.3% 3GC-R; 19.7% 3GC-S), and 13.1% for S. aureus (12.2% MRSA; 13.7% MSSA). 3GC-S but not 3GC-R E. coli BSI cases had higher adjusted hazard of death than controls (HRs, 1.73 [95% confidence interval {CI}, 1.20–2.49] and 1.38 [95% CI, .99–1.94]); risk of dying was the same for 3GC-S compared with 3GC-R infections (P = .882). Neither MSSA nor MRSA BSI patients were more likely to die than controls (HRs, 1.33 [95% CI, .91–1.93] and 1.00 [95% CI, .61–1.66]) nor MSSA versus MRSA (P = .891). The hazard of discharge alive for both resistant and susceptible S. aureus and E. coli decreased significantly when compared with controls. LOS was 2 (95% CI, 0–3) days and 1 (95% CI, −1 to 3) day longer for resistant compared with susceptible infections, for E. coli and S. aureus.
Conclusions
Antimicrobial-resistant infections were not associated with increased mortality in ACORN2. Drug-resistant BSI had longer LOS compared with susceptible infections, but CIs encompassed 0 days.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cambodia Oxford Medical Research Unit, Angkor Hospital for Children, Siem Reap, Cambodia.
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
- Antimicrobial Resistance Department, World Health Organization, Geneva, Switzerland.
- Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
- Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR.
- Department of Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana.
ORCID-Profile: Jill Hopkins, Chris Painter, Clare L Ling, Tamalee Roberts, Noah Obeng-Nkrumah, Elizabeth A Ashley, Nicholas A Feasey, Diana Kululanga, Abhilasha Karkey, Narayan Kunwar, Iruka N Okeke, Olukemi A Adekanmbi, Abiodun B Oduola, Kehinde A Ojifinni, Aaron O Aboderin, Adeyemi T Adeyemo, Ugowe Osagie, H Rogier van Doorn, Paul Turner
Förderung
- Wellcome Trust
- World Health Organization
Zitieren
APA
Hopkins, J., Tosas-Auguet, O., Waithira, N., Painter, C., Ling, C. L., Roberts, T., Miliya, T., Obeng-Nkrumah, N., Opintan, J. A., Abbeyquaye, E. P., Hamers, R. L., Saharman, Y. R., Sinto, R., Karyanti, M. R., Ibrahim, R. F., Akech, S. O., Ashley, E. A., Douangnouvong, A., Choumlivong, K., …, & ACORN Investigators (2026). Mortality and Length of Stay Associated With Community-Acquired Escherichia coli and Staphylococcus aureus Bloodstream Infections: An Observational Study in 9 Low- and Middle-Income Countries. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag275
Vancouver
Hopkins J, Tosas-Auguet O, Waithira N, Painter C, Ling CL, Roberts T, et al. Mortality and Length of Stay Associated With Community-Acquired Escherichia coli and Staphylococcus aureus Bloodstream Infections: An Observational Study in 9 Low- and Middle-Income Countries. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag275
BibTeX
@article{Hopkins2026,
author = {Hopkins, Jill and Tosas-Auguet, Olga and Waithira, Naomi and Painter, Chris and Ling, Clare L and Roberts, Tamalee and Miliya, Thyl and Obeng-Nkrumah, Noah and Opintan, Japheth A and Abbeyquaye, Emmanuel P and Hamers, Raph L and Saharman, Yulia Rosa and Sinto, Robert and Karyanti, Mulya Rahma and Ibrahim, R Fera and Akech, Samuel O and Ashley, Elizabeth A and Douangnouvong, Anousone and Choumlivong, Khamla and Feasey, Nicholas A and Kululanga, Diana and Lissauer, Samantha and Karkey, Abhilasha and Kunwar, Narayan and Erakhaiwu, Justice Enosetale and Okeke, Iruka N and Adebiyi, Ini and Adekanmbi, Olukemi A and Oduola, Abiodun B and Ogunbosi, Babatunde O and Ojifinni, Kehinde A and Tongo, Olukemi O and Ude, Ifeoma A and Aboderin, Aaron O and Adekanle, Olusegun and Adeyemo, Adeyemi T and Edward, Sylvester S and Osagie, Ugowe and Nguyen, Hoa Thi and Pham, Thach Ngoc and Van Tran, Giang and Hoàng, Hương Thị Lan and Trịnh, Tùng Hữu and van Doorn, H Rogier and Turner, Paul and Lee, Sue J and ACORN Investigators, ACORN Investigators},
title = {Mortality and Length of Stay Associated With Community-Acquired Escherichia coli and Staphylococcus aureus Bloodstream Infections: An Observational Study in 9 Low- and Middle-Income Countries},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag275}
}
EUVIMED